Replies to post #25767 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Mold illness is actually a subcategory of a broader condition that Shoemaker calls chronic inflammatory response syndrome (CIRS). CIRS is identified as “an acute and chronic, systemic inflammatory response syndrome acquired following exposure to the interior environment of a water-damaged building with resident toxigenic organisms, including, but not limited to fungi, bacteria, actinomycetes and mycobacteria as well as inflammagens such as endotoxins, beta glucans, hemolysins, proteinases, mannans and possibly spirocyclic drimanes; as well as volatile organic compounds,” according to Shoemaker’s website, SurvivingMold.

https://www.prohealth.com/library/overview-lyme-disease-mold-illness-91639

The global systemic inflammatory response syndrome treatment market was valued at ~US$ 9.3 Bn in the year 2018, and is expected to expand at a CAGR of ~8% from 2019 to 2027, to reach a value of ~US$ 17.8 Bn by 2027.

https://www.transparencymarketresearch.com/systemic-inflammatory-response-syndrome-treatment-market.html

Will VIP become our good friend?